Want to see ITGR full AI Analyst Report?
Revenue by Segment
Breaks down sales across the company’s business units or product lines to show which areas drive growth and profits. Highlights dependence on any single segment or customer, differences in margins across lines, and where future expansion or downside risk is likely to come from — essential for judging Integer’s diversification, stability of cash flow, and how acquisitions or shifts in end markets will affect results.Cardio & Vascular has been the primary growth engine and remains central to Integer’s trajectory, but management warns of temporary EP normalization that could pause that momentum; CRM&N looks steady but is flattening, while Other Markets and the non‑medical electrochem line have been effectively removed from the growth mix (portfolio exits/reclassifications), increasing reliance on core med‑tech sales. That concentration helps explain rising top‑line resilience alongside the company’s margin and cash‑flow pressures, motivating cost actions, buybacks and a board‑led strategic review.
Date | Cardio and Vascular | Cardiac Rythm Management and Neuromodulation | Other Markets | Non-medical Sales Electrochem |
|---|---|---|---|---|
Jun 30, 2026 | $280.31M | $173.71M | $10.09M | $0.00 |
Mar 31, 2026 | $261.73M | $168.26M | $9.58M | $0.00 |
Dec 31, 2025 | $284.21M | $167.30M | $20.55M | $0.00 |
Sep 30, 2025 | $277.15M | $169.16M | $21.39M | $0.00 |
Jun 30, 2025 | $286.86M | $172.00M | $17.64M | $0.00 |
Mar 31, 2025 | $258.87M | $160.34M | $18.18M | $0.00 |
Dec 31, 2024 | $255.30M | $170.52M | $23.68M | $0.00 |
Sep 30, 2024 | $241.01M | $165.09M | $25.31M | $0.00 |
Jun 30, 2024 | $231.42M | $168.06M | $28.41M | $0.00 |
Mar 31, 2024 | $221.85M | $156.93M | $29.01M | $0.00 |